Clinical trial
Combination Therapy of Interferon Alfa-2b Plus Interleukin 2 and Hepatitis B Vaccine in Entecavir-experienced Chronic Hepatitis B Patients With HBeAg Seroclearance: a Prospective, Randomized Open-label Trial (Endeavor Study, a Pilot Study)
NCT02360592 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Combination Therapy of Interferon Alfa-2b Plus Interleukin 2 and Hepatitis B Vaccine in Entecavir-experienced Chronic Hepatitis B Patients With HBeAg Seroclearance: a Prospective, Randomized Open-label Trial (Endeavor Study, a Pilot Study)
- Lead sponsor
- Tongji Hospital
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- June 30, 2013
- Completion date
- April 30, 2017
- Enrollment
- 94 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.